Astellas Pharma (OTCMKTS:ALPMY) Rating Increased to Hold at Smbc Nikko Sec.

Smbc Nikko Sec. upgraded shares of Astellas Pharma (OTCMKTS:ALPMY) to a hold rating in a research note released on Monday morning,Zacks.com reports.

Other analysts have also issued research reports about the company. Citigroup lowered Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Monday, January 19th. Zacks Research cut Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 22nd. Four equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the company presently has a consensus rating of “Hold”.

Astellas Pharma Stock Down 3.6%

Shares of OTCMKTS:ALPMY opened at $15.90 on Monday. The firm’s 50 day moving average price is $14.23 and its 200 day moving average price is $12.37. The stock has a market cap of $28.77 billion, a price-to-earnings ratio of 13.36 and a beta of 0.18. Astellas Pharma has a fifty-two week low of $8.37 and a fifty-two week high of $16.95. The company has a quick ratio of 0.80, a current ratio of 1.03 and a debt-to-equity ratio of 0.20.

Astellas Pharma (OTCMKTS:ALPMY) last posted its earnings results on Wednesday, February 4th. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.29 by $0.15. Astellas Pharma had a return on equity of 24.24% and a net margin of 15.63%.The business had revenue of $3.67 billion for the quarter, compared to analysts’ expectations of $3.21 billion. As a group, equities research analysts predict that Astellas Pharma will post 0.42 earnings per share for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).